ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy

Introduction: Mutations in the ESR1 gene (ESR1m) are important mechanisms of resistance to endocrine therapy in estrogen receptor–positive (ER+) metastatic breast cancer and have been studied as a potential therapeutic target, as well as a predictive and prognostic biomarker. Nonetheless, the role o...

Full description

Bibliographic Details
Main Authors: Tomás Reinert, Susana Ramalho, Vivian Castro Antunes de Vasconcelos, Leonardo Roberto Silva, Ana Elisa Ribeiro da Silva, Camila Annicchino de Andrade, Maria Beatriz de Paula Leite Kraft, Guilherme Portela Coelho, Jovana Mandelli, Monique Binotto, Cesar Cabello, Geisilene Russano de Paiva Silva, José Bines, Carlos H. Barrios, Matthew J. Ellis, Marcia Silveira Graudenz
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Oncology
Subjects:
breast cancer
endocrine therapy
ESR1
ESR1 mutations
neoadjuvant
aromatase inhibitors
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00342/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00342/full

Similar Items